SEC61A1 and autosomal dominant medullary cystic kidney disease with or without hyperuricemia: Thus, after genetic testing, PBA could be a potential early therapy for children with ADTKD–SEC61A1 before severe renal insufficiency occurs, which is considered a contraindication for the use of PBA.